CX-546

CX-546 belongs to the benzoxazine class of ampakines that emerged from Gary Lynch's laboratory and Cortex Pharmaceuticals as positive allosteric modulators of AMPA receptors ^[3]. Mechanistically it is a high-impact ampakine: it strongly attenuates both deactivation and desensitization of AMPA-receptor currents, producing large and prolonged excitatory responses. This makes it a powerful experimental probe but also gives it a narrower margin between cognitive facilitation and overexcitation than later low-impact compounds.

CX-546 has been central to understanding how AMPA modulation translates into durable synaptic change. Prolonged exposure prunes dendritic spines while increasing presynaptic release probability, resulting in enhanced and longer-lasting long-term potentiation in hippocampal slices ^[2]. In parallel, CX-546 and the related ampakine CX-614 elevate brain-derived neurotrophic factor expression, linking AMPA drive to neurotrophin-dependent plasticity ^[3]. A distinct line of work showed that CX-546 amplifies the energetic response of astrocytes to glutamate, increasing glucose utilization and lactate production, which suggests that cognitive enhancers acting on AMPA receptors may also recruit astrocytic metabolic support ^[1].

Despite this rich preclinical literature, CX-546 was not advanced as a therapeutic; its high-impact profile and pharmacokinetic limitations favored successor molecules. It endures as a widely cited tool compound for dissecting AMPA-dependent plasticity, neurotrophin regulation, and neuron-glia coupling.

CX-546 has essentially no human safety record; its characterization is preclinical. As a high-impact ampakine it carries a theoretical liability for overexcitation and, at extreme exposure, excitotoxic stress, which is precisely why the field shifted toward lower-impact successors. Prolonged high-dose exposure in slice models remodels synapses and prunes spines, an effect that is context-dependent and not straightforwardly beneficial. It should be regarded as a laboratory reagent rather than a substance with a defined tolerability profile in people.

CX-546 was synthesized as part of the Cortex Pharmaceuticals ampakine program built on Gary Lynch and Gary Rogers' work at the University of California, Irvine, during the 1990s and 2000s. It served as a key member of the early benzoxazine series alongside CX-516 and CX-614, and it became a favored tool for academic laboratories studying AMPA-dependent plasticity and neurotrophin regulation, even as the company prioritized other candidates for clinical development.

Among synaptic physiologists CX-546 is a well-regarded and frequently cited experimental ampakine, valued for the robustness of its effects on receptor kinetics and BDNF expression. It has little standing as a consumer nootropic because it was never marketed and its high-impact profile is considered less desirable than that of low-impact ampakines. Its lasting importance is as a research instrument.